Rethinking Research through the Cytokine Storm

Widespread efforts to combat COVID-19 have underscored a need for a personalized medicine approach in research. A greater understanding of how COVID-19 affects people individually has researchers calling for a more targeted and cross-disciplinary approach to medical research and patient care.  “There can be a tendency in the health care field to operate in silos,” says Dr. Mypinder Sekhon, a…
Read More
Entrepreneurship@UBC, a leading university incubator and accelerator, today announced the launch of its Human Health Venture (H²V) Studio, designed to leverage the University of British Columbia’s (UBC) deep pool of research by transforming human health innovations to impact through venture creation. This launch marks the program’s own evolution as an academic incubator/accelerator, creating specialized verticals to work with innovators across…
Read More

DMCBH Members Leading Four UBC Research Excellence Clusters

UBC’s Office of the Vice-President, Research & Innovation recently announced 35 emerging and established research excellence clusters that will be supported with funding in 2021/22. Four of these Research Excellence Clusters are led by DMCBH researchers. The Dynamic Brain Circuits in Health and Disease cluster seeks mechanistic insight into normal and dysfunctional brain circuits across illnesses and injuries. We accelerate these…
Read More
This week we profile a recent publication in Communications Biology from the laboratory of Dr. Calvin Yip (pictured, second from right) at UBC. One of his lab’s current research focuses is to delineate the molecular mechanism of an evolutionarily conserved pathway called autophagy. As the major pathway for the removal and recycling of intracellular materials and organelles, autophagy plays a central role in the maintenance of cellular homeostasis.
Read More
Researchers in SFU molecular biology and biochemistry professor Dr. Peter Unrau’s laboratory are working to advance the RNA World Hypothesis in answer to fundamental questions on life’s beginnings. The hypothesis suggests that life on our planet began with self-replicating ribonucleic acid (RNA) molecules, capable of not only carrying genetic information but also driving chemical reactions essential for life, prior to…
Read More
This week we profile a recent publication in Autophagy from Yasir Mohamud (pictured, right), Hui Tang (left), and Dr. Honglin Luo at UBC. The Luo Laboratory studies mechanisms of viral pathogenesis with a particular focus on heart disease and neurodegeneration while also investigating strategies to leverage oncolytic virus for cancer therapy. As common human pathogens, enteroviruses (EVs) are responsible for ~1 billion global infections annually, with severe health outcomes manifesting in vulnerable populations...
Read More
With a global demand for antibody-based therapeutics that can target cancer and other ailments, Canadian firms are stepping up. Antibody-based therapeutics have come to dominate modern medicine in recent years, and according to the Financial Post, six of the top 10 most innovative drugs globally in 2016 were antibody-related molecules. The Canadian biomedical sector hosts a number of companies advancing the…
Read More
iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or “the Company”) announced that its wholly owned subsidiary, Amphotericin B Technologies, Inc., has entered into an agreement with IIT Research Institute to test the in vivo efficacy of iCo’s novel oral amphotericin B asset (“iCo-019”) against SARS-CoV-2, the causative agent of COVID-19 in the hACE2 mouse model (the “iCo-019 Study”). iCo…
Read More
The Centre for Innovation was thrilled to once again partner with the Centre for Blood Research at the University of British Columbia to deliver their annual Lay Science Writing Competition. And with this year’s theme of “Challenges 2020”, it’s no surprise that the competition received many interesting, heartfelt and inspiring entries. The panel of esteemed judges, which included science and…
Read More
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the ALIGN Study, a pivotal phase 3 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A…
Read More